Yahoo Finance • 11 days ago
Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the co... Full story
Yahoo Finance • 16 days ago
[Usa ready for a stock market crash] franckreporter Truist Securities launched its coverage of Janux Therapeutics (NASDAQ:JANX [https://seekingalpha.com/symbol/JANX]) with a Buy recommendation and a $100 target on Wednesday, citing a cata... Full story
Yahoo Finance • last month
Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck & Co. Inc. (NYSE:MRK), with the first p... Full story
Yahoo Finance • 2 months ago
Janux Therapeutics Inc. reached a new 52-week low, with its stock price falling to 22.25 USD. This recent dip underscores a challenging year for the biotechnology company, which has seen its stock value decline by 37.03% over the past 12 m... Full story
Yahoo Finance • 2 months ago
R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the se... Full story
Yahoo Finance • 2 months ago
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 2 months ago
First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical compa... Full story
Yahoo Finance • 3 months ago
On June 11, 2025, Janux Therapeutics, Inc., a biotechnology company currently valued at $1.48 billion, conducted its 2025 Annual Meeting of Stockholders. The meeting occurred amid challenging market conditions, with the stock down over 58%... Full story
Yahoo Finance • 4 months ago
[word m and a made with wood building blocks, stock image] Maksim Labkouski Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor [https://seekingalpha.com/author/biocgt-investor],... Full story
Yahoo Finance • 5 months ago
We recently published a list of Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other unknown billionai... Full story
Yahoo Finance • 5 months ago
We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other top small cap stocks to buy wit... Full story
Yahoo Finance • 6 months ago
We recently published a list of the 12 Best Up and Coming Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Janux Therapeutics Inc. (NASDAQ:JANX) stands against other up and coming stock... Full story
Yahoo Finance • 12 months ago
We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Janux Therapeutics Inc. (NASDAQ:JANX) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps... Full story
Yahoo Finance • last year
Overview of Recent Transaction On September 12, 2024, RA Capital Management L.P., a prominent investment firm, executed a significant transaction by acquiring an additional 1,577,341 shares of Janux Therapeutics Inc (NASDAQ:JANX). This mo... Full story
Yahoo Finance • last year
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks.In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against the other biotech stocks. The ability... Full story